Business
Hemostemix Announces Aspire Health Science, LLC Has No Right to Manufacture or to Sublicense Hemostemix's Intellectual Property
Calgary, Alberta--(Newsfile Corp. - June 8, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (...
About this update from Hemostemix Inc
[{"type":"text","content":"Hemostemix Announces Aspire Health Science, LLC Has No Right to Manufacture or to Sublicense Hemostemix's Intellectual PropertyCalgary, Alberta--(Newsfile Corp. - June 8, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (\"Hemostemix\" or the \"Company\") is pleased to announce that ownership and control of its intellectual property is an uncontested fact, and the Company is in communication with each clinical trial site. The Company has lawfully and properly cancelled certain license rights to Aspire Health Science, LLC (\"Aspire\").\"Hemostemix's intellectual property is uncontested,\" said Thomas Smeenk, CEO. \"We reserve our rights to all damages against any individuals and all parties who manufacture or distribute ACP-01, or any of our intellectual property without a license and we will seek full redress against all individuals and parties,\" Smeenk said.Aspire Health Science, LLC has no license to manufacture ACP-01, nor any manufacturing rights to Hemostemix's technology whatsoever. Other than for the HS 12-01 clinical trial, any and all recipients of ACP-01 should notify health authorities, including any Internal Review Board, the FDA, Health Canada, or its jurisdictional equivalent, that they may have received illegal ACP-01, data and information from Aspire Health Science, LLC since December 6, 2019. Equally noteworthy, Aspire Health Science, LLC has no right to sublicense the Company's technology whatsoever. Any sublicense requires the approval of Hemostemix Inc., which has not been granted. The Company reiterates it has filed for an injunction before the Court of Queen's Bench, Alberta and it has been granted a hearing on June 18, 2020 at 10:00 MDT, to obtain a return of its clinical trial data and all assets. Noteworthy to-date is the fact that Aspire Health Science, LLC has failed to file a timely response to defend itself at the injunction hearing. Hemostemix's motions to dismiss Aspire's cause of action in Florida State Court, challenging defective service, jurisdiction and other issues, is tentatively set for hearing on June 25, 2020. ABOUT HEMOSTEMIX Hemostemix is a publicly traded autologous stem cell therapy company. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy,...